NASDAQ:ABP - Nasdaq - US0008471031 - Common Stock - Currency: USD
0.1948
0 (-1.57%)
The current stock price of ABP is 0.1948 USD. In the past month the price decreased by -9.4%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.15 | 329.24B | ||
AMGN | AMGEN INC | 14.09 | 157.29B | ||
GILD | GILEAD SCIENCES INC | 14.09 | 135.66B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 119.21B | ||
REGN | REGENERON PHARMACEUTICALS | 12.37 | 59.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.57B | ||
ARGX | ARGENX SE - ADR | 96.69 | 33.95B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.89 | 29.19B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.60B | ||
NTRA | NATERA INC | N/A | 20.46B | ||
INSM | INSMED INC | N/A | 19.52B | ||
BIIB | BIOGEN INC | 8.06 | 18.68B |
Abpro Holdings, Inc. operates as a capital pool company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
ABPRO HOLDINGS INC
6 St Johns Lane, Floor 5
New York City NEW YORK US
Employees: 6
Phone: 12488907200
The current stock price of ABP is 0.1948 USD. The price decreased by -1.57% in the last trading session.
The exchange symbol of ABPRO HOLDINGS INC is ABP and it is listed on the Nasdaq exchange.
ABP stock is listed on the Nasdaq exchange.
5 analysts have analysed ABP and the average price target is 2.04 USD. This implies a price increase of 947.23% is expected in the next year compared to the current price of 0.1948. Check the ABPRO HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ABPRO HOLDINGS INC (ABP) has a market capitalization of 11.84M USD. This makes ABP a Nano Cap stock.
ABPRO HOLDINGS INC (ABP) currently has 6 employees.
ABPRO HOLDINGS INC (ABP) has a support level at 0.19 and a resistance level at 0.21. Check the full technical report for a detailed analysis of ABP support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ABP does not pay a dividend.
ABPRO HOLDINGS INC (ABP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.87).
Over the last trailing twelve months ABP reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS decreased by -2966.01% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -396% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to ABP. The Buy consensus is the average rating of analysts ratings from 5 analysts.